These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25233635)

  • 1. [Pharmacokinetics of SN-38 in rats and tissue distribution of 7-ethyl-10-hydroxycamptothecin in mice after intravenous injection of irinotecan hydrochloride nanoparticles].
    Yang FY; Zhang WP; Wang XY; Yang WC; Dang HW
    Yao Xue Xue Bao; 2014 Jul; 49(7):1029-33. PubMed ID: 25233635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles].
    Yang FY; Zhang WP; Chen HL; Fu Y; Wang XY; Wei SJ; Yang XY; Zhang YX; Dang HW
    Yao Xue Xue Bao; 2013 Jun; 48(6):940-5. PubMed ID: 23984532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
    Kaneda N; Hosokawa Y; Yokokura T; Awazu S
    Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics.
    Goldwirt L; Lemaitre F; Zahr N; Farinotti R; Fernandez C
    J Pharm Biomed Anal; 2012 Jul; 66():325-33. PubMed ID: 22551773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
    Park DJ; Won JH; Cho AR; Yun HJ; Heo JH; Hwhang TH; Lee DH; Kim WM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 962():147-152. PubMed ID: 24927278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC; Vrignaud P; Lavelle F; Chabot GG
    Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes.
    Chen M; Li W; Zhang X; Dong Y; Hua Y; Zhang H; Gao J; Zhao L; Li Y; Zheng A
    Int J Nanomedicine; 2017; 12():5487-5500. PubMed ID: 28814865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of CPT-11 in rhesus monkeys.
    Inaba M; Ohnishi Y; Ishii H; Tanioka Y; Yoshida Y; Sudoh K; Hakusui H; Mizuno N; Ito K; Sugiyama Y
    Cancer Chemother Pharmacol; 1998; 41(2):103-8. PubMed ID: 9443622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
    Schluep T; Cheng J; Khin KT; Davis ME
    Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.
    Bardin S; Guo W; Johnson JL; Khan S; Ahmad A; Duggan JX; Ayoub J; Ahmad I
    J Chromatogr A; 2005 May; 1073(1-2):249-55. PubMed ID: 15909526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
    Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
    Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
    Sadzuka Y; Hirotsu S; Hirota S
    Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
    Lin LC; Wang MN; Tsai TH
    Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance of herb-drug interactions: A pharmacokinetic study on the combination administration of herbal Kang'ai injection and chemotherapy irinotecan hydrochloride injection by LC-MS/MS.
    Chen Y; Hu Z; Qi W; Gao S; Jiang J; Wang S; Xu L; Xu X; Song M; Hang T
    J Pharm Biomed Anal; 2021 Feb; 194():113784. PubMed ID: 33280996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.
    Kurita A; Kado S; Kaneda N; Onoue M; Hashimoto S; Yokokura T
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):349-60. PubMed ID: 12904895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats.
    Atsumi R; Okazaki O; Hakusui H
    Biol Pharm Bull; 1995 Aug; 18(8):1114-9. PubMed ID: 8535406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
    Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
    Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.